Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Long-term prognosis of clinically early IgA nephropathy is not always favorable

Authors: Hajeong Lee, Jin Ho Hwang, Jin Ho Paik, Hyun Jin Ryu, Dong Ki Kim, Ho Jun Chin, Yun Kyu Oh, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, Jung Pyo Lee

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

The long-term prognosis of clinically early IgA nephropathy (IgAN) patients remains to be clarified. We investigated the long-term outcomes of IgAN patients with an apparently benign presentation and evaluated prognostic factors for renal survival.

Methods

We included patients with biopsy-proven IgAN who had estimated glomerular filtration rates (eGFR) ≥60 mL/min/1.73 m2, normal blood pressure, and proteinuria <0.5 g/day at the time of biopsy. The primary outcome was progression to end-stage renal disease (ESRD). The secondary outcome was a 50% increase in serum creatinine level or an increase in proteinuria to >1 g/day.

Results

The analysis included 153 patients who met the inclusion criteria. At diagnosis, their median systolic blood pressure was 120 (110–130) mmHg, eGFR was 85.9 (74.9–100.1) mL/min/1.73 m2, and proteinuria was 0.25 (0.13–0.38) g/day. Of these, 4 patients died and 6 reached ESRD. The 30-year renal survival rate was 85.5%. Three patients had increased serum creatinine levels and 11 developed proteinuria. Remission was observed in 35 (22.9%) patients. A moderate or severe degree of interstitial fibrosis (adjusted odd ratio [OR] 5.93, 95% confidence interval [CI] 1.44–24.45, P = 0.014) and hypoalbuminemia (adjusted OR 6.18, 95% CI 1.20–31.79, P = 0.029) were independent predictors of the secondary outcome.

Conclusions

This study showed that the prognosis of early IgAN was not always favorable, even resulting in progression to ESRD in some cases. Hypoalbuminemia and interstitial fibrosis should also be considered important prognostic factors in clinically early IgAN patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, Kim S, Chin HJ: Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. Am J Nephrol. 2013, 37 (1): 74-83. 10.1159/000345960.CrossRefPubMed Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, Kim S, Chin HJ: Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. Am J Nephrol. 2013, 37 (1): 74-83. 10.1159/000345960.CrossRefPubMed
2.
go back to reference Barbour SJ, Reich HN: Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012, 59 (6): 865-873. 10.1053/j.ajkd.2012.02.326.CrossRefPubMed Barbour SJ, Reich HN: Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012, 59 (6): 865-873. 10.1053/j.ajkd.2012.02.326.CrossRefPubMed
3.
go back to reference Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med. 2013, 368 (25): 2402-2414. 10.1056/NEJMra1206793.CrossRefPubMed Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med. 2013, 368 (25): 2402-2414. 10.1056/NEJMra1206793.CrossRefPubMed
4.
go back to reference Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, Kim S, Chin HJ: Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One. 2012, 7 (12): e51225-10.1371/journal.pone.0051225.CrossRefPubMedPubMedCentral Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, Kim S, Chin HJ: Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One. 2012, 7 (12): e51225-10.1371/journal.pone.0051225.CrossRefPubMedPubMedCentral
5.
go back to reference Kiryluk K, Novak J, Gharavi AG: Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med. 2013, 64: 339-356. 10.1146/annurev-med-041811-142014.CrossRefPubMed Kiryluk K, Novak J, Gharavi AG: Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med. 2013, 64: 339-356. 10.1146/annurev-med-041811-142014.CrossRefPubMed
6.
go back to reference Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de Vinuesa S, Rojas-Rivera J, Praga M: Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012, 23 (10): 1753-1760. 10.1681/ASN.2012010063.CrossRefPubMedPubMedCentral Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de Vinuesa S, Rojas-Rivera J, Praga M: Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012, 23 (10): 1753-1760. 10.1681/ASN.2012010063.CrossRefPubMedPubMedCentral
7.
go back to reference Li PK, Ho KK, Szeto CC, Yu L, Lai FM: Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transplant. 2002, 17 (1): 64-69. 10.1093/ndt/17.1.64.CrossRefPubMed Li PK, Ho KK, Szeto CC, Yu L, Lai FM: Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transplant. 2002, 17 (1): 64-69. 10.1093/ndt/17.1.64.CrossRefPubMed
8.
go back to reference Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, Lui SF, Li PK: The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001, 110 (6): 434-437. 10.1016/S0002-9343(01)00659-3.CrossRefPubMed Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, Lui SF, Li PK: The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001, 110 (6): 434-437. 10.1016/S0002-9343(01)00659-3.CrossRefPubMed
9.
go back to reference Shen P, He L, Huang D: Clinical course and prognostic factors of clinical early IgA nephropathy. Neth J Med. 2002, 66 (6): 242-247. Shen P, He L, Huang D: Clinical course and prognostic factors of clinical early IgA nephropathy. Neth J Med. 2002, 66 (6): 242-247.
10.
go back to reference Knoop T, Vikse BE, Svarstad E, Leh S, Reisaeter AV, Bjorneklett R: Mortality in patients with IgA nephropathy. Am J Kidney Dis. 2013, 62 (5): 833-890.CrossRef Knoop T, Vikse BE, Svarstad E, Leh S, Reisaeter AV, Bjorneklett R: Mortality in patients with IgA nephropathy. Am J Kidney Dis. 2013, 62 (5): 833-890.CrossRef
11.
go back to reference Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006, 145 (4): 247-254. 10.7326/0003-4819-145-4-200608150-00004.CrossRefPubMed Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006, 145 (4): 247-254. 10.7326/0003-4819-145-4-200608150-00004.CrossRefPubMed
12.
go back to reference Lee CS, Cha RH, Lim YH, Kim H, Song KH, Gu N, Yu KS, Lim CS, Han JS, Kim S, Kim YS: Ethnic coefficients for glomerular filtration rate estimation by the Modification of Diet in Renal Disease study equations in the Korean population. J Korean Med Sci. 2010, 25 (11): 1616-1625. 10.3346/jkms.2010.25.11.1616.CrossRefPubMedPubMedCentral Lee CS, Cha RH, Lim YH, Kim H, Song KH, Gu N, Yu KS, Lim CS, Han JS, Kim S, Kim YS: Ethnic coefficients for glomerular filtration rate estimation by the Modification of Diet in Renal Disease study equations in the Korean population. J Korean Med Sci. 2010, 25 (11): 1616-1625. 10.3346/jkms.2010.25.11.1616.CrossRefPubMedPubMedCentral
13.
go back to reference Sinniah R: IgA Mesangial Nephropathy: Berger’s Disease. Am J Nephrol. 1985, 5 (2): 73-83. 10.1159/000166911.CrossRefPubMed Sinniah R: IgA Mesangial Nephropathy: Berger’s Disease. Am J Nephrol. 1985, 5 (2): 73-83. 10.1159/000166911.CrossRefPubMed
15.
go back to reference Kim SY, Jin DC, Bang BK: Current status of dialytic therapy in Korea. Nephrology. 2003, 8 (Suppl): S2-S9.CrossRefPubMed Kim SY, Jin DC, Bang BK: Current status of dialytic therapy in Korea. Nephrology. 2003, 8 (Suppl): S2-S9.CrossRefPubMed
16.
go back to reference Lai FM, Szeto CC, Choi PC, Li PK, Chan AW, Tang NL, Lui SF, Wang AY, To KF: Characterization of early IgA Nephropathy. Am J Kidney Dis. 2000, 36 (4): 703-708. 10.1053/ajkd.2000.17614.CrossRefPubMed Lai FM, Szeto CC, Choi PC, Li PK, Chan AW, Tang NL, Lui SF, Wang AY, To KF: Characterization of early IgA Nephropathy. Am J Kidney Dis. 2000, 36 (4): 703-708. 10.1053/ajkd.2000.17614.CrossRefPubMed
17.
go back to reference Koyama A, Igarashi M, Kobayashi M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 2000, 29 (4): 526-532.CrossRef Koyama A, Igarashi M, Kobayashi M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 2000, 29 (4): 526-532.CrossRef
18.
go back to reference Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, et al: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012, 8 (6): e1002765-10.1371/journal.pgen.1002765.CrossRefPubMedPubMedCentral Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, et al: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012, 8 (6): e1002765-10.1371/journal.pgen.1002765.CrossRefPubMedPubMedCentral
19.
go back to reference Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN: Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013, 84 (5): 1017-1024. 10.1038/ki.2013.210.CrossRefPubMed Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN: Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013, 84 (5): 1017-1024. 10.1038/ki.2013.210.CrossRefPubMed
20.
go back to reference Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med. 1998, 339 (20): 1448-1456. 10.1056/NEJM199811123392007.CrossRefPubMed Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med. 1998, 339 (20): 1448-1456. 10.1056/NEJM199811123392007.CrossRefPubMed
21.
go back to reference Daniel L, Saingra Y, Giorgi R, Bouvier C, Pellissier JF, Berland Y: Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis. 2000, 35 (1): 13-20. 10.1016/S0272-6386(00)70295-2.CrossRefPubMed Daniel L, Saingra Y, Giorgi R, Bouvier C, Pellissier JF, Berland Y: Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis. 2000, 35 (1): 13-20. 10.1016/S0272-6386(00)70295-2.CrossRefPubMed
22.
go back to reference Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol. 2012, 8 (5): 275-283. 10.1038/nrneph.2012.58.CrossRefPubMed Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol. 2012, 8 (5): 275-283. 10.1038/nrneph.2012.58.CrossRefPubMed
23.
go back to reference Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, et al: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009, 76 (5): 534-545. 10.1038/ki.2009.243.CrossRefPubMed Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, et al: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009, 76 (5): 534-545. 10.1038/ki.2009.243.CrossRefPubMed
24.
go back to reference Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, Chung BH, Park CW, Yang CW, Kim YS, Choi YJ, Choi BS: The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012, 27 (1): 252-258. 10.1093/ndt/gfr295.CrossRefPubMed Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, Chung BH, Park CW, Yang CW, Kim YS, Choi YJ, Choi BS: The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012, 27 (1): 252-258. 10.1093/ndt/gfr295.CrossRefPubMed
25.
go back to reference Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N: Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012, 7 (6): e38904-10.1371/journal.pone.0038904.CrossRefPubMedPubMedCentral Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N: Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012, 7 (6): e38904-10.1371/journal.pone.0038904.CrossRefPubMedPubMedCentral
26.
go back to reference Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011, 305 (15): 1553-1559. 10.1001/jama.2011.451.CrossRefPubMed Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011, 305 (15): 1553-1559. 10.1001/jama.2011.451.CrossRefPubMed
27.
go back to reference Keane WF, Brenner BM, De Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003, 63 (4): 1499-1507. 10.1046/j.1523-1755.2003.00885.x.CrossRefPubMed Keane WF, Brenner BM, De Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003, 63 (4): 1499-1507. 10.1046/j.1523-1755.2003.00885.x.CrossRefPubMed
Metadata
Title
Long-term prognosis of clinically early IgA nephropathy is not always favorable
Authors
Hajeong Lee
Jin Ho Hwang
Jin Ho Paik
Hyun Jin Ryu
Dong Ki Kim
Ho Jun Chin
Yun Kyu Oh
Kwon Wook Joo
Chun Soo Lim
Yon Su Kim
Jung Pyo Lee
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-94

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.